Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Influenza Resistance Information Study (IRIS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00884117
First received: April 15, 2009
Last updated: June 8, 2016
Last verified: June 2016

April 15, 2009
June 8, 2016
January 2009
November 2015   (final data collection date for primary outcome measure)
  • Number of Participants With Genotypic Resistance [ Time Frame: Baseline (Day 1) and post-Baseline (Days 3, 6, 10) ] [ Designated as safety issue: No ]
    Samples were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR). Pre-defined mutations in viral ribonucleic acid (RNA) were noted, the presence of which was defined as genotypic resistance. The number of participants with genotypic resistance at Baseline was reported. The number of participants with genotypic resistance post-Baseline was determined by a collective count of all participants who had a resistance mutation at least once on Days 3, 6, and/or 10. (Hereafter, "H" stands for hemagglutinin and "N" stands for neuraminidase in abbreviations of viral subtype such as H1N1, H1N1pdm09, and H3N2.)
  • Percentage of Participants Exhibiting Treatment-Emergent Resistance by Study Year Among Participants With H3N2 or H1N1pdm09 Infections [ Time Frame: From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) during Study Years 1, 2, 3, 4, 5, 6, 7 ] [ Designated as safety issue: No ]
    Pre-defined mutations in viral RNA were noted, the presence of which was defined as genotypic resistance. Treatment-emergent resistance was defined as the presence of genotypic or phenotypic resistance from a post-Baseline sample in the setting of a previously non-resistant Baseline sample. The percentage of participants with treatment-emergent resistance was reported by study year for participants with H3N2 or H1N1pdm09 infections. Only data with evaluable participants were reported.
Not Provided
Complete list of historical versions of study NCT00884117 on ClinicalTrials.gov Archive Site
  • Number of Participants With Viral RNA Detected by RT-PCR on Day 1 Among Adults Treated With Oseltamivir [ Time Frame: Baseline (Day 1) ] [ Designated as safety issue: No ]
  • Number of Participants With Viral RNA Detected by RT-PCR on Day 3 Among Adults Treated With Oseltamivir [ Time Frame: Day 3 ] [ Designated as safety issue: No ]
  • Number of Participants With Viral RNA Detected by RT-PCR on Day 6 Among Adults Treated With Oseltamivir [ Time Frame: Day 6 ] [ Designated as safety issue: No ]
  • Number of Participants With Viral RNA Detected by RT-PCR on Day 10 Among Adults Treated With Oseltamivir [ Time Frame: Day 10 ] [ Designated as safety issue: No ]
  • Number of Participants With Viral RNA Detected by RT-PCR on Day 1 Among Children Treated With Oseltamivir [ Time Frame: Baseline (Day 1) ] [ Designated as safety issue: No ]
  • Number of Participants With Viral RNA Detected by RT-PCR on Day 3 Among Children Treated With Oseltamivir [ Time Frame: Day 3 ] [ Designated as safety issue: No ]
  • Number of Participants With Viral RNA Detected by RT-PCR on Day 6 Among Children Treated With Oseltamivir [ Time Frame: Day 6 ] [ Designated as safety issue: No ]
  • Number of Participants With Viral RNA Detected by RT-PCR on Day 10 Among Children Treated With Oseltamivir [ Time Frame: Day 10 ] [ Designated as safety issue: No ]
  • Time to Non-Detection of Viral RNA [ Time Frame: From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) ] [ Designated as safety issue: No ]
    Time to non-detection/viral clearance was the time between symptom onset and the day on which viral RNA was no longer detected, or the last visit date if the participant was not RNA-negative at that visit. Time to non-detection/viral clearance was estimated using Kaplan-Meier analysis and expressed in days.
  • Time to Non-Detection of Viral RNA Among Participants With H3N2 Infections [ Time Frame: From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) ] [ Designated as safety issue: No ]
    Time to non-detection/viral clearance was the time between symptom onset and the day on which viral RNA was no longer detected, or the last visit date if the participant was not RNA-negative at that visit. Time to non-detection/viral clearance was estimated using Kaplan-Meier analysis and expressed in days.
  • Time to Non-Detection of Viral RNA Among Participants With H1N1pdm09 Infections [ Time Frame: From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) ] [ Designated as safety issue: No ]
    Time to non-detection/viral clearance was the time between symptom onset and the day on which viral RNA was no longer detected, or the last visit date if the participant was not RNA-negative at that visit. Time to non-detection/viral clearance was estimated using Kaplan-Meier analysis and expressed in days.
  • Time to Non-Detection of Viral RNA Among Participants With Influenza B Infections [ Time Frame: From Baseline (Day 1) to Day 10 (assessed on Days 1, 3, 6, 10) ] [ Designated as safety issue: No ]
    Time to non-detection/viral clearance was the time between symptom onset and the day on which viral RNA was no longer detected, or the last visit date if the participant was not RNA-negative at that visit. Time to non-detection/viral clearance was estimated using Kaplan-Meier analysis and expressed in days.
  • Viral Load Among Adults Treated With Oseltamivir [ Time Frame: Days 1, 3, 6, 10 ] [ Designated as safety issue: No ]
    Viral load was determined for those with detectable virus above the lower limit of quantification (LLQ) of 1.82 for influenza A viruses and 1.99 for influenza B viruses. The viral load from each sample was averaged among all participants and expressed in log10 of the number of viral particles per milliliter (log10 vp/mL).
  • Viral Load Among Children Treated With Oseltamivir [ Time Frame: Days 1, 3, 6, 10 ] [ Designated as safety issue: No ]
    Viral load was determined for those with detectable virus above the LLQ of 1.82 for influenza A viruses and 1.99 for influenza B viruses. The viral load from each sample was averaged among all participants and expressed in log10 vp/mL.
  • Percentage of Participants With Symptom Resolution on Day 6 Comparing Resistant and Susceptible Viruses [ Time Frame: Day 6 ] [ Designated as safety issue: No ]
    Pre-defined mutations in viral RNA were noted, the presence of which was defined as genotypic resistance. Phenotypic resistance was defined as 50% inhibitory concentration (IC50) more than 10-fold higher than the median value for all viruses of the same subtype. Treatment-emergent resistance was defined as the presence of genotypic or phenotypic resistance from a post-Baseline sample in the setting of a previously non-resistant Baseline sample. Susceptible viruses were those that did not exhibit treatment-emergent resistance. The percentage of participants with mild or absent symptoms on Day 6 was reported and stratified by resistant and susceptible viruses.
  • Percentage of Participants by Day of Viral RNA First Not Detected Comparing Resistant and Susceptible Viruses [ Time Frame: Days 3, 6, 10 ] [ Designated as safety issue: No ]
    Pre-defined mutations in viral RNA were noted, the presence of which was defined as genotypic resistance. Phenotypic resistance was defined as IC50 more than 10-fold higher than the median value for all viruses of the same subtype. Treatment-emergent resistance was defined as the presence of genotypic or phenotypic resistance from a post-Baseline sample in the setting of a previously non-resistant Baseline sample. Susceptible viruses were those that did not exhibit treatment-emergent resistance. The percentage of participants by earliest post-Baseline test day on which viral RNA was not detected was reported and stratified by resistant and susceptible viruses.
  • Percentage of Participants With Resistant Versus Susceptible Viruses by Baseline Viral Load [ Time Frame: Baseline (Day 1) ] [ Designated as safety issue: No ]
    Pre-defined mutations in viral RNA were noted, the presence of which was defined as genotypic resistance. Phenotypic resistance was defined as IC50 more than 10-fold higher than the median value for all viruses of the same subtype. Treatment-emergent resistance was defined as the presence of genotypic or phenotypic resistance from a post-Baseline sample in the setting of a previously non-resistant Baseline sample. Susceptible viruses were those that did not exhibit treatment-emergent resistance. The mean viral load from each sample was expressed in log10 vp/mL and stratified by resistant and susceptible viruses.
  • Total Daily Symptom Score According to Global Assessment by the Investigator Among Adults Treated With Oseltamivir [ Time Frame: Days 1, 6, 10 ] [ Designated as safety issue: No ]
    Symptoms were assessed on Days 1, 6, and 10. The Investigator rated seven symptoms of fever, sore throat, nasal congestion, cough, aches/pains, headache, and fatigue on a scale of 0 (absent/no problem) to 3 (severe/major problem). The global score was calculated as a sum of all individual symptom scores. Global scores may range from 0 to 21, with higher scores indicating worse or more pronounced symptoms.
  • Total Daily Symptom Score According to Global Assessment by the Investigator Among Children Treated With Oseltamivir [ Time Frame: Days 1, 6, 10 ] [ Designated as safety issue: No ]
    Symptoms were assessed on Days 1, 6, and 10. The Investigator rated seven symptoms of fever, sore throat, nasal congestion, cough, aches/pains, headache, and energy/tiredness on a scale of 0 (absent/no problem) to 3 (severe/major problem). The global score was calculated as a sum of all individual symptom scores. Global scores may range from 0 to 21, with higher scores indicating worse or more pronounced symptoms.
  • Body Temperature Among Adults Treated With Oseltamivir [ Time Frame: Days 1, 10 ] [ Designated as safety issue: No ]
    Body temperature was measured by the Investigator using an oral or tympanic thermometer at Baseline and Day 10. Body temperature at each visit was averaged among all participants and expressed in degrees Celsius.
  • Change From Baseline in Body Temperature Among Adults Treated With Oseltamivir [ Time Frame: Baseline (Day 1) to Day 10 ] [ Designated as safety issue: No ]
    Body temperature was measured by the Investigator using an oral or tympanic thermometer at Baseline and Day 10. The change in body temperature between visits was averaged among all participants and expressed in degrees Celsius.
  • Body Temperature Among Children Treated With Oseltamivir [ Time Frame: Days 1, 10 ] [ Designated as safety issue: No ]
    Body temperature was measured by the Investigator using an oral or tympanic thermometer at Baseline and Day 10. Body temperature at each visit was averaged among all participants and expressed in degrees Celsius.
  • Change From Baseline in Body Temperature Among Children Treated With Oseltamivir [ Time Frame: Baseline (Day 1) to Day 10 ] [ Designated as safety issue: No ]
    Body temperature was measured by the Investigator using an oral or tympanic thermometer at Baseline and Day 10. The change in body temperature between visits was averaged among all participants and expressed in degrees Celsius.
Not Provided
Not Provided
Not Provided
 
Influenza Resistance Information Study
Influenza Resistance Information Study (IRIS)
This study will assist in the early detection of influenza resistant to antivirals and will monitor the clinical outcome of adults and children infected with influenza according to subtype and susceptibility. Participants clinically diagnosed with influenza will undergo a rapid diagnostic test and viral sampling at Baseline and on Days 3, 6, and 10. Participants will be clinically managed according to local guidelines and the decision to treat/not treat will be at the discretion of the Investigator.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Participants with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness will be enrolled.
Influenza
Drug: Oseltamivir
Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.
Other Name: Tamiflu
Participants Infected with Influenza
Participants with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness will be enrolled and followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. Participants may receive treatment including oseltamivir, other treatment/medication, or no treatment.
Intervention: Drug: Oseltamivir
Fraaij PL, Schutten M, Javouhey E, Burleigh L, Outlaw R, Kumar D, Boucher CA. Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS). Antivir Ther. 2015;20(6):633-42. doi: 10.3851/IMP2957. Epub 2015 Apr 7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4561
November 2015
November 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants greater than or equal to (≥) 1 year of age with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness (during Years 1 to 5)
  • Participants less than or equal to (≤) 12 years of age with a positive diagnostic test of influenza and displaying symptoms suggestive of influenza-like illness and who are being or, according to local standard of care, will be treated with an influenza antiviral (during Years 6 and 7)

Exclusion Criteria:

  • Allergy to any potential influenza therapy
  • Living in the same household or residential/care home as another study participant
Both
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   France,   Germany,   Hong Kong,   Netherlands,   Norway,   Poland
 
NCT00884117
NV20237, 2008-006149-24
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP